![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Phase III Data Show Significant Benefit of Novartis Drug Afinitor in Patients With Non-Cancerous Tumors Associated With TSC
Phase III Data Show Significant Benefit of Novartis Drug Afinitor in Patients With Non-Cancerous Tumors Associated With TSC
January 11, 2013
Data published in The Lancet shows patients on Afinitor (everolimus) tablets with non-cancerous kidney tumors associated with tuberous sclerosis complex (TSC) experienced a significant reduction in tumor size and the absence of tumor progression.
PR Newswire
PR Newswire
Upcoming Events
-
21Oct